Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Meeting the Entry of Wal-Mart: JACDS Seminar
July 1, 2002
- Korosho to Finalize Drug Industry Vision by Summer
July 1, 2002
- Functional Food Foundation Set Up
July 1, 2002
- Less than Half of Companies Have PAL Compliance System
July 1, 2002
- OTC NEWS IN BRIEF
July 1, 2002
- Clinical Efficacy Is More Important in Selecting Comparator Drugs: Dr Yazaki of DPO
July 1, 2002
- WORLD NEWS IN BRIEF
July 1, 2002
- FPMAJ Proposes Concrete Application Rule for New NHI Pricing Method
July 1, 2002
- Pharmacia to Double Sales, Enter Top 10 in 2005: Mr Yamaki
July 1, 2002
- 75% of the Elderly Enjoy Healthy Life: White Paper
July 1, 2002
- Basic Policy for FY2003 Budget Formation Recommended by Council
July 1, 2002
- Expert Panel Presents Interim Report on IP
July 1, 2002
- REGULATORY NEWS IN BRIEF
July 1, 2002
- Good Initial Market Reactions to Olmesartan: Mr Shoda of Sankyo
July 1, 2002
- Number of ADRs Totals 26,545 in FY2001
July 1, 2002
- Wholesalers' Cooperation Is Essential in Immediate PMS: Teijin
July 1, 2002
- Clinical Research GL to Be Compiled by Korosho Working Group
July 1, 2002
- Nippon Chemiphar to Promote Uralyt Based on GLs
July 1, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 1, 2002
- Taiyo Pharm Aims at Sales of Over \20 Bil. in FY2002
July 1, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…